Follow-up of premature children with high risk for growth and development delay: a multiprofessional assessment

Marcia de Freitas1, Ana Merzel Kernkraut1, Simone Maria Amadio Guerrero2

  • 1Maternal and Infant Department, Hospital Israelita Albert Einstein - HIAE, São Paulo, SP, BR.

Insights

This study evaluated premature newborns using a multiprofessional team, finding most showed improved development by 24 months corrected age. Early intervention and continued follow-up are crucial for high-risk infants.

Area of Science:

  • Neonatal development
  • Pediatric rehabilitation
  • Developmental pediatrics

Background:

  • Premature newborns face significant developmental risks.
  • Multiprofessional assessment is key for early detection of developmental delays.
  • Outpatient clinics provide specialized care for high-risk infants.

Purpose of the Study:

  • To describe the activities of a multiprofessional outpatient clinic.
  • To evaluate the development of premature newborns.
  • To identify developmental outcomes in preterm infants.

Main Methods:

  • Twenty premature infants (birth weight <1250g or <32 weeks gestation) were assessed.
  • Development was evaluated using the Bayley III scale at corrected ages of 3, 6, 9, 12, 18, and 24 months.
  • A team including neonatologists, therapists, and psychologists provided comprehensive evaluations.

Main Results:

  • Mean gestational age was 28.8 weeks; mean birth weight was 1055g.
  • Fifteen percent had impaired sensorimotor skills, 20% hearing abnormalities, and 10% motor alterations.
  • Developmental delays were most prominent between 6-18 months, with improvement by 24 months.

Conclusions:

  • Most evaluated premature infants demonstrated improved growth and development by 24 corrected-age months.
  • Parental guidance and targeted interventions were provided.
  • Further research with larger samples and longer follow-up into primary school is recommended.
Abstract

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
22.8K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
372
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
702
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
330
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
461
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
733